FDA reviewing Acadia's Parkinson drug

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) sank 22% to $15.20 on April 25 after CNN reported that FDA is re-examining the safety of Nuplazid pimavanserin, which is approved to treat Parkinson's disease psychosis (PDP). An FDA spokesperson told BioCentury that the agency's review of available information on the drug has been ongoing for "several weeks."

Safety concerns for Nuplazid were re-ignited on April 9 after CNN highlighted a November 2017 safety report from the non-profit group Institute for Safe Medication Practices (ISMP), which identified 244 deaths among 2,236 adverse event reports filed for patients taking the drug (see BioCentury, April 13)...